GB2054371A - Long-acting parenteral compositions of haloperidol and bromperidol derivatives - Google Patents

Long-acting parenteral compositions of haloperidol and bromperidol derivatives Download PDF

Info

Publication number
GB2054371A
GB2054371A GB8018117A GB8018117A GB2054371A GB 2054371 A GB2054371 A GB 2054371A GB 8018117 A GB8018117 A GB 8018117A GB 8018117 A GB8018117 A GB 8018117A GB 2054371 A GB2054371 A GB 2054371A
Authority
GB
United Kingdom
Prior art keywords
composition
gt
lt
haloperidol
bromperidol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB8018117A
Other versions
GB2054371B (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP8082679A priority Critical patent/JPS568318A/en
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of GB2054371A publication Critical patent/GB2054371A/en
Application granted granted Critical
Publication of GB2054371B publication Critical patent/GB2054371B/en
Application status is Expired legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/52Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4

Abstract

Long-acting neuraleptic compositions for parenteral, in particular intramuscular or subcutaneous, administration, comprise a decanoate ester of haloperidol or bromperidol in sesame oil as a solvent. The esters may be prepared by known methods.

Description

SPECIFICATION Long-acting parenteral compositions of haloperidol and bromperidol derivatives Haloperidol, being chemically designated as 4 -L4 (4 - chlorophenyl) -4 - hydroxy - 1 - piperidinylj - 1 - (4 -fluorophenyl) - 1 - butanone, and bromperidol, being chemically designated as 4 -[4 - (4 bromophenyl) -4 - hydroxy - 1 - piperidinylj - 1 - (4 - fluorophenyl) - 1 - butanone, are both well-known psychotropic agents belonging to the class of4 piperidinols which are described in Japanese Pat.

No.300,049.

Structurally, haloperidol and bromperidol are represented by the formula <img class="EMIRef" id="027282656-00010001" />

wherein X is respectively chloro (haloperidol) or bromo (bromperidol).

The compounds are powerful psychotropic drugs which can be used in psychotropic therapy permitting the return to normal pursuits of patients who otherwise might require prolonged or repeated hospitalization.

After initial recovery or discharge of the patients it is advisable and mostly indispensable to continue the therapy with a maintenance dose to prevent the frequent relapses which are recorded at varying lengths of time after the suspension of treatment.

Although parenteral administration is replaced by oral administration, as soon as possible, many times it is not practicable and then the frequency of injection gets burdensome. This frequency of injection, which is oftentimes accompanied by tissue irritation, makes it desirable to find a composition for intramuscular administration which preserves the psychotropic properties of haloperidol or bromperidol while the frequency of administration can be reduced.

In U.S. Pat. No. 3,408,356 there are described a series of longchain esters of piperidinols and in particular, long-chain esters of 1 - (4 - fluorophenyl) - 4 {4 -[ - 3 - (trifluoromiethyl) phenyl )J -4 - hydroxy - 1 - piperidinyl} - 1 - butanone, which is generally known as trifluperidol ortriperidol. Also disclosed are pharmaceutical compositions comprising said long-chain esters in suitable vehicles. According to U.S. Pat. No. 3,408,356 the concerned compounds exhibit prolonged tranquilizing activity, particularly in the treatment of mental disorders.

The present invention is specifically concerned with pharmaceutical compositions comprising a decanoic acid ester of haloperidol or bromperidol in sesame oil as a solvent.

The decanoic acid esters, which are used as active ingredients in the compositions according to the present invention, may be represented by the formula <img class="EMIRef" id="027282656-00010002" />

wherein X is chloro or bromo.

The subject compositions of the present invention are highly efficaceous and at the same time remarkably safe and almost completely free of any undesired side-effects. More especially, when administered to warm-blooded animals, the said compositions provoke a long-lasting and nevertheless uniform psychotropic effect, which can be varied in duration to up to several weeks depending upon the concentration and the amount of decanoic acid ester which is present in the composition.

The compositions of the present invention have been found remarkably free of excitatory and extrapyramidal side-effects which are rather frequently encountered during trifluperidol therapy. It is evident that a reduction or even complete absence of such side-effects are a prerequisite to a therapy with long-acting psychotropic agents since such effects, if existing, will continue during a long period of time, even after interruption of the treatment. The reduction of these side-effects or even the complete disappearance thereof renders the compositions of the present invention particularly attractive for longterm parenteral therapy. In this respect the subject compositions show a marked superiority over any long-acting psychotropic compositions presently in use.

It has been found that the intramuscular or subcutaneous administration of piperidinols such as haloperidol and bromperidol is often associated with tissue irritation. Quite unexpectedly, the compositions of the present invention are found to be sub stantial ly free of any tissue irritation.

The compounds of formula (II) may easily be prepared by acylating haloperidol (I-a) or bromperidol (I-b)with decanoyl chloride (III). <img class="EMIRef" id="027282656-00010003" />

(I-a) X = Cl (I-b) X Said acylating reaction is preferably carried out following art-known acylating procedures, such as by stirring the reactants together, if desired, in the presence of a suitable solvent, e.g., N,N -dimethyl- formamide, N,N dimethylacetamide, acetonitrile, 2 - propanone, and the like. Somewhat elevated temp eratures are appropriate to enhance the rate of the reaction. Most preferably the reaction is carried out in the presence of an appropriate base, e.g., sodium carbonate, pyridine and the like, to captivate the hydrochloric acid which is liberated during the course of the reaction.

The preparations of the piperidinols of formula (I) are generally known. They may be prepared following one of the procedures described in the literature, e.g., following one of the procedures described in Japanese Pat. No. 300,049.

The effectiveness and the extended duration of action ofthe compositions comprising a decanoate ester of haloperidol or bromperidol can be demonstrated by apomorphine emesis studies. Apomorphine hydrochloride is a central emetic which induces vomiting within a few minutes after subcutaneous injection, except when the test-animals are pretreated with effective neuroleptics. The duration of effectiveness may be determined by chronic induction of apomorphine emesis.

Appropriately selected dogs are injected intramuscularly in the biceps femoris with a test dose. Four hours after dosing and 90 minutes following feeding, apomorphine hydrochloride (0.31 mg/kg) is injected subcutaneously. The animals are observed during 30 minutes following the injection.

Thereafter, the apomorphine hydrochloride is administered daily, 90 minutes following feeding, and observations of the response made during 30 minutes. The duration of action is the period between the first absence of emetic response and the first of three consecutive positive emetic responses.

Table I illustratesthe median duration of action, the test being carried out on 5 dogs.

Table I <img class="EMIRef" id="027282656-00020001" />

<tb> <SEP> Compound <SEP> Dose <SEP> Median <SEP> duration <SEP> of <tb> <SEP> mg/kg <SEP> action <SEP> (days) <tb> haloperidol <SEP> 2.5 <SEP> 5 <tb> haloperidol <SEP> decanoate <SEP> 2.5 <SEP> 21 <tb> bromperidol <SEP> 1.5 <SEP> 4 <tb> bromperidol <SEP> decanoate <SEP> 1.5 <SEP> 19 <tb> The compositions according to the present invention may contain a suitable antimicrobial preservative but other additives normally are not necessary.

An example of such a preservative is benzyl alcohol.

The compositions may be prepared in a conventional manner, e.g., by admixing the ester with the preservative, if present, and then with the sesame oil. The concentration of the decanoic acid ester may be from about 30 to about 150 mg per milliliter.

By the present invention there is also provided a method of effecting psychotropic therapy which comprises administering to a subject needing such therapy, a psychotropically effective amount of a compound of formula (II) in a composition according to the invention. Psychotropic therapy may generally be effected by administering such compositions in an amount sufficient to supplyfrom 0.4 to 20 mg of active ingredient per kg of body weight.

The preferred route of administration is intramuscular although subcutaneous administration may also be employed.

The following examples are intended to illustrate and not to limit the scope of the present invention.

Example I To a warmed suspension of 37.6 parts of 4 -[4 - (4 chlorophenyl) -4 - hydroxy -1 - piperidinylj - 1 - (4 - fluorophenyl) - 1 - butanone in 320 parts of prop anone are added successively 15.3 parts of N,N diethylethanamine and 28.9 parts of decanoyl chloride. The resulting mixture is heated and refluxed for 18 hours. After cooling the mixture is filtered and the filtrate is evaporated under reduced pressure, yielding a residue which is triturated with 1,1' -oxybisethaneto separate the triethylamine hydrochloride by-product.The filtrate is concentrated and purified by column-chromatography using 1,1' - oxybisethane as eluent, yielding 33 parts (66.3%) of 4 - (4 - chlorophenyl ) -1 - L4 - (4 - fluorophenyl) - 4 - oxobutylj - 4- piperidinyl decano- ate, as a viscous oil.

Example II To a stirred and warm (60"C) solution of 10 parts of 4 (4 - (4!- bromophenyl) -4 - hydroxy -1 piperidinylt - t - (4 - fluorophenyl ) - 1 - butanone in 90 parts of N,N - dimethylformamide are added dropwise 5.76 parts decanoyl chloride. Upon completion, stirring at 600C is continued overnight. The reaction mixture is cooled and poured onto water. The mix ture is alkalized with a sodium hydroxide solution 2N. The aqueous phase is decanted and the sticky oil is dissolved in 1,1' - oxybisethane at room tempera- ture whereupon the unreacted starting material is filtered off. The 1,1' oxybisethane -phase is washed twice with water, dried, filtered and evaporated. The oily residue is purified by columnchromatography over silica gel using 1,1' oxybisethane as eluent, yielding 8.4 parts of4 - (4 - bromophenyl) - 1 -[4 - (4 fluorophenyl) - 4 - oxobutylj - 4- piperidinyl decanoate as an oii.

Example III Injectable compositions are prepared by intermixing the components: composition A: Haloperidol decanoate 70.5 grams Benzyl alcohol 12 grams Sesame oil, q.s. ad 1 liter composition B: Haloperidol decanoate 141 grams Benzyl alcohol 12 grams Sesame oil, q.s. ad 1 liter composition C: Bromoperidol decanoate 34 grams Benzyl alcohol 12 gram Sesame oil, q.s. ad 1 liter composition D: Bromperidol decanoate 136 grams Benzyl alcohol 12 grams Sesame oil, q.s. ad 1 liter.

Claims (8)

1. A psychotropic composition, suitable for parenteral administration, comprising sesame oil as a solvent and as an active ingredient an effective psychotropic amount of a decanoic acid ester having the formula: <img class="EMIRef" id="027282657-00030001" />
wherein X is a chlorine or bromine atom.
2. A composition as claimed in claim 1 comprising from 30 mg to 150 mg of 4 - (4 - chlorophenyl) -1 -[4-(4-fluorophenyl )-4-oxo-butylJ -4 piperidinyl decanoate per ml.
3. A composition as claimed in claim 1 comprising from 30 mg to 150 mg of 4 - (4 - bromophenyl) - 1 -[4-(4-fluorophenyl)-4-oxo-butylj - 4 - piperidinyl decanoate per ml.
4. A composition as claimed in claim 2 which is suitable for intramuscular and subcutaneous administration.
5. A composition as claimed in claim 3 which is suitable for intramuscual and subcutaneous administration.
6. Acomposition as claimed in any one ofthe preceding claims which contains an antimicrobial preservative.
7. A composition as claimed in claim 6 wherein the preservative in benzyl alcohol.
8. A composition as claimed in claim 1 substantially as hereinbefore described.
GB8018117A 1979-06-28 1980-06-03 Long-acting parenteral compositions of haloperidol and bromperidol derivatives Expired GB2054371B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8082679A JPS568318A (en) 1979-06-28 1979-06-28 Non oral long acting composition of haloperidol and bromperidol derivative

Publications (2)

Publication Number Publication Date
GB2054371A true GB2054371A (en) 1981-02-18
GB2054371B GB2054371B (en) 1983-08-03

Family

ID=13729223

Family Applications (1)

Application Number Title Priority Date Filing Date
GB8018117A Expired GB2054371B (en) 1979-06-28 1980-06-03 Long-acting parenteral compositions of haloperidol and bromperidol derivatives

Country Status (9)

Country Link
JP (1) JPS568318A (en)
BE (1) BE883994A (en)
CY (1) CY1255A (en)
DE (1) DE3024305C2 (en)
FR (1) FR2460932B1 (en)
GB (1) GB2054371B (en)
HK (1) HK83384A (en)
KE (1) KE3427A (en)
NL (1) NL190775C (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260070A1 (en) * 1986-09-11 1988-03-16 H. Lundbeck A/S The acetic acid ester of haloperidol and pharmaceutical compositions thereof
US5428036A (en) * 1990-10-03 1995-06-27 H. Lundbeck A/S Sertindole prodrugs, compositions and use
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN103301461A (en) * 2012-03-08 2013-09-18 江苏豪森药业股份有限公司 Long-acting injectable preparation, preparation method and application thereof
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US9861699B2 (en) 2012-09-19 2018-01-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US10085980B2 (en) 2014-03-20 2018-10-02 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10226458B2 (en) 2011-03-18 2019-03-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0669128T3 (en) * 1992-11-17 2000-06-19 Yoshitomi Pharmaceutical The sustained-release microsphere containing antipsychotic and process for producing same
EP0937053A1 (en) 1996-10-31 1999-08-25 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Sustained-release derivatives of hydroxylated analogs of substituted 1- 2 bis(aryl)methoxy]ethyl]-piperazines and -homopiperazines and their use as noncompetitive antagonists of dopamine reuptake

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408356A (en) * 1965-08-31 1968-10-29 Squibb & Sons Inc Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like
DE1695194A1 (en) * 1966-07-11 1971-03-18 Hoffmann La Roche A process for the preparation of piperidine derivatives
US3850935A (en) * 1971-10-16 1974-11-26 Sumitomo Chemical Co Process for producing piperidine derivatives by degrading quaternary piperidinium salts

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260070A1 (en) * 1986-09-11 1988-03-16 H. Lundbeck A/S The acetic acid ester of haloperidol and pharmaceutical compositions thereof
US5428036A (en) * 1990-10-03 1995-06-27 H. Lundbeck A/S Sertindole prodrugs, compositions and use
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US9556155B2 (en) 2006-05-09 2017-01-31 Genzyme Corporation Methods of treating fatty liver disease
US9745294B2 (en) 2007-05-31 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8940776B2 (en) 2007-05-31 2015-01-27 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US10220039B2 (en) 2007-10-05 2019-03-05 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8729075B2 (en) 2008-07-28 2014-05-20 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9272996B2 (en) 2008-10-03 2016-03-01 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9744153B2 (en) 2008-10-03 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US10226458B2 (en) 2011-03-18 2019-03-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising sorbitan esters
CN103301461A (en) * 2012-03-08 2013-09-18 江苏豪森药业股份有限公司 Long-acting injectable preparation, preparation method and application thereof
CN103301461B (en) * 2012-03-08 2018-09-07 江苏豪森药业集团有限公司 Long-acting injectable formulation and preparation method and use thereof
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
US10004807B2 (en) 2012-03-19 2018-06-26 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty acid esters
US9993556B2 (en) 2012-03-19 2018-06-12 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising fatty glycerol esters
US9861699B2 (en) 2012-09-19 2018-01-09 Alkermes Pharma Ireland Limited Pharmaceutical compositions having improved storage stability
US10085980B2 (en) 2014-03-20 2018-10-02 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds
US10238651B2 (en) 2014-03-20 2019-03-26 Alkermes Pharma Ireland Limited Aripiprazole formulations having increased injection speeds

Also Published As

Publication number Publication date
GB2054371B (en) 1983-08-03
BE883994A (en) 1980-12-29
FR2460932B1 (en) 1984-11-16
NL8003583A (en) 1980-12-30
CY1255A (en) 1984-08-31
DE3024305C2 (en) 1989-12-07
NL190775B (en) 1994-03-16
JPS568318A (en) 1981-01-28
HK83384A (en) 1984-11-09
KE3427A (en) 1984-08-10
DE3024305A1 (en) 1981-01-22
NL190775C (en) 1994-08-16
BE883994A2 (en)
FR2460932A1 (en) 1981-01-30

Similar Documents

Publication Publication Date Title
US3574843A (en) 1,4-dihydropyridine derivatives for the treatment of angina pectoris
US3236857A (en) 2-(phenyl-amino)-1, 3-diazacyclopentene-(2) substitution products
CA1100875A (en) Tetracycline antibiotic compositions
EP0002482B1 (en) 4-hydroxy-2h-1,2-benzothiazine-3-carboxamide-1,1-dioxides, processes for their preparation and pharmaceutical compositions containing them
EP0004279B1 (en) Process for the preparation of 4-pyridone-3-carboxylic acids, 1-cyclopropyl-4-pyridone-3-carboxylic acid derivatives and medicines containing them
EP0126355B1 (en) 7-amino-1-cyclopropyl-6,8-difluoro-1,4-dihydro-4-oxo-3-quinoline-carboxylic acid, processes for their preparation and antibacterial agents containing them
US4603136A (en) Monoheteroring compounds and their use
EP0005205B1 (en) Substituted 5.6-dimethylpyrrolo(2,3-d)pyrimidines, methods for their preparation and medicines containing them
US4093734A (en) Amino-benzoic acid amides
DE3021792C2 (en)
EP0259804B1 (en) Pyrido[3,2,1-ij]-1,3,4-benzoxadiazine derivatives, process for their preparation, resulting pharmaceutical preparations and intermediates for use in the process
BR0110240A (en) A compound, a process for preparing a compound, process for producing an antibacterial effect in a warm-blooded animal, using a compound, and pharmaceutical composition
AR015769A1 (en) Imidazo pyridine derivatives that inhibit gastric acid secretion, processes for preparing such derivatives, pharmaceutical composition, use of these derivatives for preparing medicaments and intermediate compounds.
EP0153277B1 (en) Pleuromutilin derivatives, process for their preparation and their use
DE3702393A1 (en) 8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids, a process for their preparation and antibacterial agents containing
EP0043659B1 (en) Clonidine derivatives useful in the treatment of diarrhoea
DD202149A5 (en) A process for the preparation of 5-substituted oxazolidine-2,4-diones
EP0121176A1 (en) Indolinone-2 derivatives, process for their preparation, medicines containing them and intermediate compounds
TR200100300T2 (en) amide derivatives useful as inhibitors of the production of cytokines
EP0170117B1 (en) Oxindole derivatives, process for their preparation, pharmaceutical compositions containing them and intermediate compounds
JP2011063620A (en) Derivative of piperidine and piperazine
US3949089A (en) Substituted guanidine compounds as antifibrillatory agents
CH671576A5 (en)
US4460588A (en) 5-Substituted pyrimidine derivatives active against internal animal parasites
EP0287907A1 (en) Pyrazolo[3,4-d]pyrimidines, process for their preparation and use as pharmaceutical compounds

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20000602